Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics

Publication date: June 2020Source: Nano Today, Volume 32Author(s): Fei Gong, Nailin Yang, Xianwen Wang, Qi Zhao, Qian Chen, Zhuang Liu, Liang ChengAbstractThe design and development of tumor microenvironment (TME)-responsive intelligent nanoplatforms have attracted increasing interest to enhance the therapeutic effects of drugs, due to their potential to address some significant therapeutic issues, such as unsatisfying therapeutic outcomes and serious side effects. In this review, we mainly summarize the strategies used to construct these nanoplatforms based on characteristic factors present at high levels in the TME, including acidic pH values, endogenous H2O2, over-expressed enzymes, hypoxia-induced by insufficient oxygen supply, excess level of GSH, and other factors. These nanoplatforms that utilize the enhanced permeability and retention (EPR) effect and TME-triggered drug delivery enhance the therapeutic outcomes, minimize the side effects, and achieve image-guided therapy. Furthermore, the limitations and prospects of these nanoplatforms for enhanced cancer therapy are also discussed.Graphical abstractSchematic illustration showed endogenously responsive intelligent nanoplatforms (acidic pH, H2O2, enzymes, GSH, hypoxia, vessel, and dual/multiple-responsive) for cancer theranostics.
Source: Nano Today - Category: Nanotechnology Source Type: research

Related Links:

Authors: Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, Brattain MG, Natarajan A Abstract [This corrects the article DOI: 10.18632/oncotarget.23749.]. PMID: 32637035 [PubMed - in process]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: November 2020Source: Materials Science and Engineering: C, Volume 116Author(s): Yong Sze Ong, Manuel Bañobre-López, Sofia A. Costa Lima, Salette Reis
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
iubellino The proto-oncogene MET, the hepatocyte growth factor (HGF) receptor, is a transmembrane receptor tyrosine kinase (RTK) with a prominent role in tumor metastasis and resistance to anti-cancer therapies. Melanoma demonstrates relatively frequent MET aberrations, including MET gene amplification. Concurrently, programmed death-ligand 1 (PD-L1), with its ability to evade anti-tumor immune responses, has emerged as a prominent therapeutic target in melanoma and other malignancies and its expression is used as a predictive biomarker of response to immunotherapy. We performed immunohistochemistry analysis of MET and...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This article focuses on imaging illustrations with differential diagnosis for various emergency scenarios related to acute abdomen specifically in oncologic settings.
Source: Abdominal Imaging - Category: Radiology Source Type: research
Incorporating skin toxicity protocols at a cancer center significantly increased the rate of prophylactic treatment for rashes resulting from cancer therapies.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation. Int J Mol Med. 2020 Aug;46(2):795-805 Authors: Zinnah KMA, Seol JW, Park SY Abstract Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) is a potential target for cancer therapy, owing to its ability to selectively kill cancer cells without causing significant toxicity to normal cells. However, due to the lack of death receptor expression, cancer cells can become highly resistant to TRAIL. Hence, it is vital to develop agents that restore TRAIL efficacy. Sertral...
Source: International Journal of Molecular Medicine - Category: Molecular Biology Authors: Tags: Int J Mol Med Source Type: research
Authors: Li Y, Hou H, Zhang P, Zhang Z Abstract Nanoparticle-based drug delivery system offers a promising platform for combination cancer therapy. However, the inefficient drug release in cells reduces the therapeutic efficacy of cancer nanomedicines. Herein, a PEGylated poly(α-lipoic acid) copolymer (mPEG-PαLA) was prepared and used as a reduction/pH dual responsive nanocarrier to simultaneously deliver paclitaxel (PTX) and doxorubicin (DOX) for osteosarcoma therapy. The amphiphilic mPEG-PαLA could efficiently encapsulate both PTX and DOX during its self-assembly into micelles in aqueous solutio...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c07608
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
Success in cancer treatment over the last four decades has ranged from improvements in classical drug therapy to immune oncology. Anti-cancer drugs have also often proven beneficial for the treatment of inflammatory and autoimmune diseases. In this review, we report on challenging examples that bridge between treatment of cancer and immune-mediated diseases, addressing mechanisms and experimental models as well as clinical investigations. Patient-derived tumor xenograft (PDX) (humanized) mouse models represent useful tools for preclinical evaluation of new therapies and biomarker identification. However, new developments u...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractAG36 is a triterpenoid saponin fromArdisia gigantifolia stapf. Our recent studies proved that AG36 displayed prominent cytotoxicity against breast cancer cells both in vitro and in vivo. However, whether AG36 has antiangiogenic properties is unknown. Therefore, in the present study, we evaluated the antiangiogenic effect of AG36 and the underlying mechanism. The results indicated that AG36 could significantly inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC). Further antiangiogenic molecular mechanism investigation showed that AG36 significantly suppressed phosphory...
Source: Journal of Natural Medicines - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Nanotechnology